Hepatobiliary Cancer clinical trials
12 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
- Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
- Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
- Intravital Microscopy in Human Solid Tumors
- Social Determinants of Health in Hepatobiliary Cancer Patients
- Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Acceptance and Commitment Therapy (ACT-HBC) for the Improvement of Cancer Distress in Patients With Hepatobiliary Cancers
- Targeted Navigation in Hepatocellular Carcinoma (HCC)
- BOLSTER: Learning New Skills to Thrive
- EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Hepatobiliary Cancer” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.